<DOC>
	<DOCNO>NCT00673049</DOCNO>
	<brief_summary>The objective study test clinical benefit addition CP 751,871 erlotinib therapy patient advance NSCLC non adenocarcinoma histology . The primary endpoint Overall Survival ( OS ) .</brief_summary>
	<brief_title>Trial Of CP-751 , 871 And Erlotinib In Refractory Lung Cancer</brief_title>
	<detailed_description>This study terminate March 8 , 2010 due analysis independent Data Safety Monitoring Committee ( DSMC ) indicate addition CP-751,871 [ figitumumab ] erlotinib [ Tarceva ] would unlikely meet primary endpoint improve overall survival compare erlotinib alone . This Oncology study continue terminate , however ethical reason patient , note resultant benefit , continue receive treatment .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Large Cell</mesh_term>
	<mesh_term>Carcinoma , Adenosquamous</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Non small cell lung cancer primary histology squamous cell , large cell adenosquamous carcinoma . At least 1 measurable lesion , define RECIST . Primary NSCLC adenocarcinoma subtypes unknown/unspecified histology . Prior Erlotinib therapy . Prior anti IGF IR base investigational therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>IGR-1R</keyword>
	<keyword>Non small cell lung cancer</keyword>
	<keyword>CP-751</keyword>
	<keyword>871</keyword>
	<keyword>Figitumumab</keyword>
</DOC>